Faricimab▼ in Neovascular Age-Related Macular Degeneration: Efficacy, Safety, and Durability Through Week 48 in TENAYA and LUCERNE
This presentation reports the pooled week 48 primary results, including the proportion of patients with an absence of retinal fluid through week 12, from the phase 3 TENAYA and LUCERNE trials of faricimab▼ , a bispecific antibody that independently binds and neutralizes Ang-2 and VEGF-A, in patients with neovascular age-related macular degeneration. TENAYA and LUCERNE investigated the efficacy, safety, and durability of faricimab▼ , administered at individualized treatment intervals of up to every 16 weeks compared with aflibercept administered every 8 weeks.